Headlines about Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) have been trending somewhat positive on Friday, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tonix Pharmaceuticals Holding Corp. earned a news impact score of 0.14 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.3992515192211 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern’s analysis:
- Tonix Pharmaceuticals : Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya for PTSD (4-traders.com)
- BRIEF-Tonix Pharma reports outcomes from CMC guidance meeting with FDA on Tonmya (reuters.com)
- Tonix Pharma (TNXP) Says in General Its Proposed CMC Data Package to Support Tonmya’s NDA and Commercial … – StreetInsider.com (streetinsider.com)
- Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) for PTSD (finance.yahoo.com)
- Tonix Pharmaceuticals : to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference (4-traders.com)
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded down 0.97% during trading on Friday, reaching $4.08. 24,725 shares of the company were exchanged. Tonix Pharmaceuticals Holding Corp. has a 52-week low of $2.85 and a 52-week high of $9.40. The firm has a 50-day moving average of $4.31 and a 200-day moving average of $4.12. The firm’s market cap is $30.63 million.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.13. On average, equities analysts forecast that Tonix Pharmaceuticals Holding Corp. will post ($3.02) EPS for the current year.
TNXP has been the subject of a number of research reports. Dawson James restated a “buy” rating and set a $9.00 target price on shares of Tonix Pharmaceuticals Holding Corp. in a report on Wednesday, August 23rd. Drexel Hamilton initiated coverage on shares of Tonix Pharmaceuticals Holding Corp. in a report on Tuesday, August 22nd. They set a “buy” rating for the company. Roth Capital upgraded shares of Tonix Pharmaceuticals Holding Corp. from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a report on Friday, August 18th. They noted that the move was a valuation call. Aegis initiated coverage on shares of Tonix Pharmaceuticals Holding Corp. in a report on Monday, June 26th. They set a “buy” rating and a $10.00 target price for the company. Finally, ValuEngine upgraded shares of Tonix Pharmaceuticals Holding Corp. from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $8.33.
WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Tonix Pharmaceuticals Holding Corp. (TNXP) Share Price” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://sportsperspectives.com/2017/10/20/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-tonix-pharmaceuticals-holding-corp-tnxp-share-price.html.
In other news, CEO Seth Lederman acquired 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was purchased at an average price of $3.00 per share, for a total transaction of $60,000.00. Following the completion of the acquisition, the chief executive officer now owns 11,166 shares in the company, valued at $33,498. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.00% of the stock is currently owned by insiders.
Tonix Pharmaceuticals Holding Corp. Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.